CS
SANA icon

Credit Suisse’s Sana Biotechnology SANA Stock Holding History

Credit Suisse’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.25M Buy
124,622
+5,575
+5% +$41.8K ﹤0.01% 2133
2023
Q4 		$486K Buy
119,047
+14,048
+13% +$51.8K ﹤0.01% 2744
2023
Q3 		$406K Sell
104,999
-15,091
-13% -$81.1K ﹤0.01% 2793
2023
Q2 		$716K Buy
120,090
+21,139
+21% +$122K ﹤0.01% 2603
2023
Q1 		$324K Buy
98,951
+9,461
+11% +$37.8K ﹤0.01% 2964
2022
Q4 		$353K Buy
89,490
+20,929
+31% +$102K ﹤0.01% 2951
2022
Q3 		$411K Buy
68,561
+9,082
+15% +$65.5K ﹤0.01% 2904
2022
Q2 		$382K Buy
59,479
+34,545
+139% +$220K ﹤0.01% 3012
2022
Q1 		$206K Buy
24,934
+1,493
+6% +$12.1K ﹤0.01% 3366
2021
Q4 		$364K Buy
+23,441
New +$452K ﹤0.01% 4032

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse's SANA Position: Q1 2024 in Review

Credit Suisse increased its Sana Biotechnology (SANA) stake by 4.7% in Q1 2024, buying an estimated $41.8K and bringing the position to 124,622 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

Credit Suisse first reported a position in SANA in Q4 2021 and has held it in 10 quarters since. 154 funds tracked by Wall St. Rank hold SANA as of Q1 2024.

  • Credit Suisse held 124,622 shares of Sana Biotechnology worth $1.25M as of Q1 2024.
  • Credit Suisse bought 5,575 Sana Biotechnology shares in Q1 2024, an estimated $41.8K.
  • Sana Biotechnology made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2133 holding.
  • Credit Suisse first reported a position in Sana Biotechnology in Q4 2021 and has held it in 10 quarters since.
  • 154 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.